Mack Roach, III, MD
Professor
Radiation Oncology
School of Medicine

Education & Training

Show all (1) Hide

• M.D. School of Medicine Stanford University 1979

Websites

Show all (1) Hide

• Clinical Profile at UCSF Medical Center (ucsfhealth.org)

Grants and Projects

Show all (2) Hide

• NAPTA: Optimizing clinical trial design & delivery of particle therapy for cancer, NIH, 2015-2018
• SFSU/UCSF Comprehensive Cancer Partnership Program, NIH, 2002-2010

Publications (312)

Top publication keywords:
Radiotherapy, AdjuvantProstateProstatectomyRadiotherapy, Intensity-ModulatedSalvage TherapyAntineoplastic Agents, HormonalBrachytherapyAndrogen AntagonistsProstate-Specific AntigenGoserelinRadiotherapyRadiotherapy DosageProstatic NeoplasmsRadiotherapy, ConformalRadiation Injuries

• Phase 3 Trial of Dose-Escalated Radiation Therapy and Standard Androgen Deprivation Therapy Versus Dose-Escalated Radiation Therapy and Enhanced Androgen Deprivation Therapy With Orteronel for Men With High-Risk Prostate Cancer (NRG/RTOG 1115).
  International journal of radiation oncology, biology, physics 2025 Hamstra DA, Dignam JJ, Bruner DW, Michaelson MD, Bachand F, Master V, Torres MA, Saylor PJ, Wallace RE, Vapiwala N, Efstathiou JA, Roach M, Rosenthal SA, Raben A, Morgan SC, Kavadi VS, Spratt DE, …
• Radiotherapy- Versus Surgery-based Treatment Strategy in High-risk Prostate Cancer.
  European urology oncology 2025 Roy S, Sun Y, Eastham JA, Gleave M, Wallis CJD, Beltran HA, Kishan AU, Jia AY, Zaorsky NG, Nagar H, Garcia JA, Small EJ, Nguyen P, Attard G, McKay RR, Sartor O, Berlin A, Rosenthal SA, Halabi S, Vince…
• Assessing Algorithmic Fairness With a Multimodal Artificial Intelligence Model in Men of African and Non-African Origin on NRG Oncology Prostate Cancer Phase III Trials.
  JCO clinical cancer informatics 2025 Roach M, Zhang J, Mohamad O, van der Wal D, Simko JP, DeVries S, Huang HC, Joun S, Schaeffer EM, Morgan TM, Keim-Malpass J, Chen E, Yamashita R, Monson JM, Naz F, Wallace J, Bahary JP, Wilke D, Batra …
• Real-world analyses of major adverse cardiovascular events and mortality risk after androgen deprivation therapy initiation in black vs. white prostate cancer patients.
  Prostate cancer and prostatic diseases 2025 Moul JW, Boldt-Houle DM, Roach M
• Bridging the Gap: Enhancing Prostate Cancer Survivorship and Advocacy Among Ethnically Diverse Black Men Through Community Town Halls.
  Journal of cancer education : the official journal of the American Association for Cancer Education 2025 Ogunsanya ME, Kaninjing E, DeForge SM, Morton DJ, Cole P, Beckford P, Reese D, Mitchell T, Montgomery E, Odeleye R, Miró-Rivera EY, Roberts K, Neil JM, Alexander AC, Funk-Lawler RK, Azizoddin D, Roach…

Show all (307 more) Hide

• MRI-Linac-Based Radiotherapy-Promising or Hype?
  JAMA oncology 2024 Roach M, Ling S, Coleman PW
• Delayed definitive management of localized prostate cancer: what do we know?
  Prostate cancer and prostatic diseases 2024 Mohamad O, Li YR, Feng F, Hong JC, Wong A, El Kouzi Z, Shelan M, Zilli T, Carroll P, Roach M
• Pragmatic clinical trials for localized prostate cancer: lessons learned and "three sins".
  Frontiers in oncology 2024 Roach M
• NCCN Guidelines® Insights: Prostate Cancer, Version 3.2024.
  Journal of the National Comprehensive Cancer Network : JNCCN 2024 Schaeffer EM, Srinivas S, Adra N, An Y, Bitting R, Chapin B, Cheng HH, D'Amico AV, Desai N, Dorff T, Eastham JA, Farrington TA, Gao X, Gupta S, Guzzo T, Ippolito JE, Karnes RJ, Kuettel MR, Lang JM, …
• Disparities in the Delivery of Prostate Cancer Survivorship Care in the USA: A Claims-based Analysis of Urinary Adverse Events and Erectile Dysfunction Among Prostate Cancer Survivors.
  European urology open science 2024 Mmonu N, Kamdar N, Roach M, Sarma A, Makarov D, Zabar S, Breyer B
• Primary cancer prevention for cancers with no known infectious etiology: Time for a new paradigm.
  Vaccine 2024 Black S, Roach M, Rappuoli R
• Cardiovascular Mortality and Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-term Update of NRG/RTOG 9202.
  European urology focus 2024 Mak KS, Scannell Bryan M, Dignam JJ, Shipley WU, Lin Y, Peters CA, Gore EM, Rosenthal SA, Zeitzer KL, D'Souza DP, Horwitz EM, Pisansky TM, Maier JM, Chafe SM, Robin TP, Roach M, Tran PT, Souhami L, …
• The National Cancer Institute's Cancer Disparities Research Partnership Program: a unique funding model 20 years later.
  Journal of the National Cancer Institute 2023 Coleman CN, Wong R, Petereit DG, Maguire PD, Heron DE, Steinberg M, Bains Y, Vikram B, Angelis P, Livinski AA, Roach M, Govern FS
• Prostate Cancer, Race, and Health Disparity: What We Know.
  Cancer journal (Sudbury, Mass.) 2023 Roach M, Coleman PW, Kittles R
• Age 70 +/- 5 Years and Cancer-Specific Outcomes After Treatment of Localized Prostate Cancer: A Systematic Review.
  International journal of radiation oncology, biology, physics 2023 Shaheen H, Salans MA, Mohamad O, Coleman PW, Ahmed S, Roach M
• Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology.
  Journal of the National Comprehensive Cancer Network : JNCCN 2023 Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R, Bryce A, Chapin B, Cheng HH, D'Amico AV, Desai N, Dorff T, Eastham JA, Farrington TA, Gao X, Gupta S, Guzzo T, Ippolito JE, Kuettel MR, …
• Racism Might Cause Prostate Cancer and Definitely Causes Excess Unemployment, Lost Wages, and Excess Cancer Deaths.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023 Roach M, Chapman C, Coleman PW
• Effect of Brachytherapy With External Beam Radiation Therapy Versus Brachytherapy Alone for Intermediate-Risk Prostate Cancer: NRG Oncology RTOG 0232 Randomized Clinical Trial.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023 Michalski JM, Winter KA, Prestidge BR, Sanda MG, Amin M, Bice WS, Gay HA, Ibbott GS, Crook JM, Catton CN, Raben A, Bosch W, Beyer DC, Frank SJ, Papagikos MA, Rosenthal SA, Barthold HJ, Roach M, …
• Development and External Validation of a Machine Learning Model for Prediction of Lymph Node Metastasis in Patients with Prostate Cancer.
  European urology oncology 2023 Sabbagh A, Washington SL, Tilki D, Hong JC, Feng J, Valdes G, Chen MH, Wu J, Huland H, Graefen M, Wiegel T, Böhmer D, Cowan JE, Cooperberg M, Feng FY, Roach M, Trock BJ, Partin AW, D'Amico AV, Carroll…
• Author Correction: Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials.
  NPJ digital medicine 2023 Esteva A, Feng J, van der Wal D, Huang SC, Simko JP, DeVries S, Chen E, Schaeffer EM, Morgan TM, Sun Y, Ghorbani A, Naik N, Nathawani D, Socher R, Michalski JM, Roach M, Pisansky TM, Monson JM, Naz F,…
• AUA/ASTRO 2022 Guidelines: "Scrutinized".
  Practical radiation oncology 2023 Roach Iii M, Coleman PW, Sabol RA
• Effects of Androgen Deprivation Therapy on Prostate Cancer Outcomes According to Competing Event Risk: Secondary Analysis of a Phase 3 Randomised Trial.
  European urology 2023 Mell LK, Pugh SL, Jones CU, Nelson TJ, Zakeri K, Rose BS, Zeitzer KL, Gore EM, Bahary JP, Souhami L, Michalski JM, Hartford AC, Mishra MV, Roach M, Parliament MB, Choi KN, Pisansky TM, Husain SM, …
• Re: Understanding the Role of Urology Practice Organization and Racial Composition in Prostate Cancer Treatment Disparities.
  JCO oncology practice 2023 Roach M, Coleman PW
• Analysis of a Biopsy-Based Genomic Classifier in High-Risk Prostate Cancer: Meta-Analysis of the NRG Oncology/Radiation Therapy Oncology Group 9202, 9413, and 9902 Phase 3 Randomized Trials.
  International journal of radiation oncology, biology, physics 2022 Nguyen PL, Huang HR, Spratt DE, Davicioni E, Sandler HM, Shipley WU, Efstathiou JA, Simko JP, Pollack A, Dicker AP, Roach M, Rosenthal SA, Zeitzer KL, Mendez LC, Hartford AC, Hall WA, Desai AB, …
• Five-Year Patient-Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer.
  International journal of radiation oncology, biology, physics 2022 Lukka HR, Deshmukh S, Bruner DW, Bahary JP, Lawton CAF, Efstathiou JA, Kudchadker RJ, Ponsky LE, Seaward SA, Dayes IS, Gopaul DD, Michalski JM, Delouya G, Kaplan ID, Horwitz EM, Roach M, Feng FY, Pugh…
• Body composition and mortality in men receiving prostate radiotherapy: A pooled analysis of NRG/RTOG 9406 and NRG/RTOG 0126.
  Cancer 2022 McDonald AM, DeMora L, Yang ES, Hoyle JM, Lenzie A, Williams GR, Michalski JM, Yee D, Bahary JP, Den RB, Roach M, Dess R, Mishra MV, Valicenti RK, Lau HY, Marcrom SR, Souhami L, Mendez LC, Chen Y, …
• Editorial Comment.
  The Journal of urology 2022 Sabol RA, Roach M
• NCCN Guidelines® Insights: Prostate Cancer, Version 1.2023.
  Journal of the National Comprehensive Cancer Network : JNCCN 2022 Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R, Bryce A, Chapin B, Cheng HH, D'Amico AV, Desai N, Dorff T, Eastham JA, Farrington TA, Gao X, Gupta S, Guzzo T, Ippolito JE, Kuettel MR, …
• Sequencing of Androgen-Deprivation Therapy of Short Duration With Radiotherapy for Nonmetastatic Prostate Cancer (SANDSTORM): A Pooled Analysis of 12 Randomized Trials.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022 Ma TM, Sun Y, Malone S, Roach M, Dearnaley D, Pisansky TM, Feng FY, Sandler HM, Efstathiou JA, Syndikus I, Hall EC, Tree AC, Sydes MR, Cruickshank C, Roy S, Bolla M, Maingon P, De Reijke T, Nabid A, …
• Local Failure Events in Prostate Cancer Treated with Radiotherapy: A Pooled Analysis of 18 Randomized Trials from the Meta-analysis of Randomized Trials in Cancer of the Prostate Consortium (LEVIATHAN).
  European urology 2022 Ma TM, Chu FI, Sandler H, Feng FY, Efstathiou JA, Jones CU, Roach M, Rosenthal SA, Pisansky T, Michalski JM, Bolla M, de Reijke TM, Maingon P, Neven A, Denham J, Steigler A, Joseph D, Nabid A, Souhami…
• Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials.
  NPJ digital medicine 2022 Esteva A, Feng J, van der Wal D, Huang SC, Simko JP, DeVries S, Chen E, Schaeffer EM, Morgan TM, Sun Y, Ghorbani A, Naik N, Nathawani D, Socher R, Michalski JM, Roach M, Pisansky TM, Monson JM, Naz F,…
• Moving Beyond Race-Based Medicine.
  Annals of internal medicine 2022 Roach M
• Race, Biology, Disparities, and Prostate Cancer.
  European urology 2022 Vickers AJ, Elfiky A, Freeman VL, Roach M
• Commentary: Race, COVID-19 and Nursing Homes.
  The Journal of infectious diseases 2022 Roach M, Hiatt RA, Black S
• Comparison of Response to Definitive Radiotherapy for Localized Prostate Cancer in Black and White Men: A Meta-analysis.
  JAMA network open 2021 Ma TM, Romero T, Nickols NG, Rettig MB, Garraway IP, Roach M, Michalski JM, Pisansky TM, Lee WR, Jones CU, Rosenthal SA, Wang C, Hartman H, Nguyen PL, Feng FY, Boutros PC, Saigal C, Chamie K, Jackson …
• Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings.
  European journal of cancer (Oxford, England : 1990) 2021 Vogl UM, Beer TM, Davis ID, Shore ND, Sweeney CJ, Ost P, Attard G, Bossi A, de Bono J, Drake CG, Efstathiou E, Fanti S, Fizazi K, Halabi S, James N, Mottet N, Padhani AR, Roach M, Rubin M, Sartor O, …
• Salvage Low-Dose-Rate Prostate Brachytherapy: Clinical Outcomes of a Phase 2 Trial for Local Recurrence after External Beam Radiation Therapy (NRG Oncology/RTOG 0526).
  International journal of radiation oncology, biology, physics 2021 Crook J, Rodgers JP, Pisansky TM, Trabulsi EJ, Amin MB, Bice W, Morton G, Murtha AD, Vigneault E, Helou J, Michalski JM, Roach M, Beyer D, Jani AB, Horwitz EM, Raben A, Pugh S, Sandler H
• Current and Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer (mCRPC).
  Biomedicines 2021 Henríquez I, Roach M, Morgan TM, Bossi A, Gómez JA, Abuchaibe O, Couñago F
• Adding Short-Term Androgen Deprivation Therapy to Radiation Therapy in Men With Localized Prostate Cancer: Long-Term Update of the NRG/RTOG 9408 Randomized Clinical Trial.
  International journal of radiation oncology, biology, physics 2021 Jones CU, Pugh SL, Sandler HM, Chetner MP, Amin MB, Bruner DW, Zietman AL, Den RB, Leibenhaut MH, Longo JM, Bahary JP, Rosenthal SA, Souhami L, Michalski JM, Hartford AC, Amin PP, Roach M, Yee D, …
• Salvage High-Dose-Rate Brachytherapy for Recurrent Prostate Cancer After Definitive Radiation.
  Practical radiation oncology 2021 Wu SY, Wong AC, Shinohara K, Roach M, Cunha JAM, Valdes G, Hsu IC
• Radiotherapy of oligometastatic prostate cancer: a systematic review.
  Radiation oncology (London, England) 2021 Rogowski P, Roach M, Schmidt-Hegemann NS, Trapp C, von Bestenbostel R, Shi R, Buchner A, Stief C, Belka C, Li M
• Radiation Delay Is Okay, but Where Is the Evidence?
  JAMA oncology 2021 Mohamad O, Roach M
• Considering benefit and risk before routinely recommending SpaceOAR.
  The Lancet. Oncology 2021 Hall WA, Tree AC, Dearnaley D, Parker CC, Prasad V, Roach M, Lawton CAF
• Stereotactic Body Radiation Therapy and High-Dose-Rate Brachytherapy Boost in Combination With Intensity Modulated Radiation Therapy for Localized Prostate Cancer: A Single-Institution Propensity Score Matched Analysis.
  International journal of radiation oncology, biology, physics 2020 Chen WC, Li Y, Lazar A, Altun A, Descovich M, Nano T, Ziemer B, Sudhyadhom A, Cunha A, Thomas H, Gottschalk A, Hsu IC, Roach M
• Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis-Free Survival Compared to Neoadjuvant ADT: An Individual Patient Meta-Analysis.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2020 Spratt DE, Malone S, Roy S, Grimes S, Eapen L, Morgan SC, Malone J, Craig J, Dess RT, Jackson WC, Hartman HE, Kishan AU, Mehra R, Kaffenberger S, Morgan TM, Reichert ZR, Alumkal JJ, Michalski J, Lee …
• Long-Term Results of NRG Oncology/RTOG 0321: A Phase II Trial of Combined High Dose Rate Brachytherapy and External Beam Radiation Therapy for Adenocarcinoma of the Prostate.
  International journal of radiation oncology, biology, physics 2020 Hsu IC, Rodgers JP, Shinohara K, Purdy J, Michalski J, Roach M, Vigneault E, Ivker RA, Pryzant RM, Kuettel M, Taussky D, Gustafson GS, Raben A, Sandler HM
• Assessment of Postprostatectomy Radiotherapy as Adjuvant or Salvage Therapy in Patients With Prostate Cancer: A Systematic Review.
  JAMA oncology 2020 Sachdev S, Carroll P, Sandler H, Nguyen PL, Wafford E, Auffenberg G, Schaeffer E, Roach M, Evans CP, Hussain M
• Delaying Dilemmas: Coronavirus Complications Impacting the Management of Prostate Cancer.
  International journal of radiation oncology, biology, physics 2020 Mohamad O, Roach M
• Phase II trial of SM-88, a cancer metabolism based therapy, in non-metastatic biochemical recurrent prostate cancer.
  Investigational new drugs 2020 Gartrell BA, Roach M, Retter A, Sokol GH, Del Priore G, Scher HI
• Editorial Comment.
  The Journal of urology 2020 Roach M
• Dramatic response to combination pembrolizumab and radiation in metastatic castration resistant prostate cancer.
  Therapeutic advances in medical oncology 2020 Han HJ, Li YR, Roach M, Aggarwal R
• Clinical recommendations in the management of advanced prostate cancer: International Gastrointestinal, Liver and Uro-oncology (IGILUC 2019) experts.
  World journal of urology 2020 Elghazaly H, Mottet N, Garcia J, Oudard S, Roach M, Abbou C, Merseburger A, Emara A, Shehata S, Tawfik H, Khorshid O, Selim A, Assem A, Abdelkarim K, Ezz El-Arab L, Bazarbashi S, Omar A, Elwakil H, …
• The Roach Equation: Value of Old Clinical Tools in the Era of New Molecular Imaging.
  Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2020 Li YR, Roach M
• Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2020 Jackson WC, Hartman HE, Dess RT, Birer SR, Soni PD, Hearn JWD, Reichert ZR, Kishan AU, Mahal BA, Zumsteg ZS, Efstathiou JA, Kaffenberger S, Morgan TM, Mehra R, Showalter TN, Krauss DA, Nguyen PL, …
• Understanding High-Dose, Ultra-High Dose Rate, and Spatially Fractionated Radiation Therapy.
  International journal of radiation oncology, biology, physics 2020 Griffin RJ, Ahmed MM, Amendola B, Belyakov O, Bentzen SM, Butterworth KT, Chang S, Coleman CN, Djonov V, Formenti SC, Glatstein E, Guha C, Kalnicki S, Le QT, Loo BW, Mahadevan A, Massaccesi M, Maxim …
• Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019.
  European urology 2020 Gillessen S, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Chi KN, Clarke N, Davis ID, de Bono J, Drake CG, Duran I, Eeles R, Efstathiou E, Evans CP, Fanti S, Feng FY, …
• Re: Identifying the Optimal Candidate for Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer: Results from a Large, Multi-institutional Analysis.
  European urology 2019 Li YR, Roach M
• Development of Treatments for Localized Prostate Cancer in Patients Eligible for Active Surveillance: U.S. Food and Drug Administration Oncology Center of Excellence Public Workshop.
  The Journal of urology 2019 Weinstock C, Suzman D, Kluetz P, Baxley J, Viviano C, Ibrahim A, Jarow J, Sridhara R, Liu K, Carroll P, Eggener S, Hu JC, Hussain M, King M, Klein E, Kungel T, Makarov D, Pinto PA, Rini B, Roach M, …
• Association of Black Race With Prostate Cancer-Specific and Other-Cause Mortality.
  JAMA oncology 2019 Dess RT, Hartman HE, Mahal BA, Soni PD, Jackson WC, Cooperberg MR, Amling CL, Aronson WJ, Kane CJ, Terris MK, Zumsteg ZS, Butler S, Osborne JR, Morgan TM, Mehra R, Salami SS, Kishan AU, Wang C, …
• Stampede to Cure.
  International journal of radiation oncology, biology, physics 2019 Li YR, Roach M
• Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.
  Journal of the National Comprehensive Cancer Network : JNCCN 2019 Mohler JL, Antonarakis ES, Armstrong AJ, D'Amico AV, Davis BJ, Dorff T, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Hurwitz M, Ippolito JE, Kane CJ, Kuettel MR, Lang JM, McKenney J, …
• Prostate-Specific Antigen After Neoadjuvant Androgen Suppression in Prostate Cancer Patients Receiving Short-Term Androgen Suppression and External Beam Radiation Therapy: Pooled Analysis of Four NRG Oncology Radiation Therapy Oncology Group Randomized Clinical Trials.
  International journal of radiation oncology, biology, physics 2019 Hallemeier CL, Zhang P, Pisansky TM, Hanks GE, McGowan DG, Roach M, Zeitzer KL, Firat SY, Husain SM, D'Souza DP, Souhami L, Parliament MB, Rosenthal SA, Lukka HR, Rotman M, Horwitz EM, Miles EF, …
• The association between BMI and BSA-temozolomide-induced myelosuppression toxicities: a correlative analysis of NRG oncology RTOG 0525.
  Neuro-oncology practice 2019 Robins HI, Eickhoff J, Gilbert MR, Armstrong TS, Shi W, De Groot JF, Schultz CJ, Hunter GK, Valeinis E, Roach M, Youssef EF, Souhami L, Howard SP, Lieberman FS, Herman JG, Zhang P, Mehta MP
• A Systematic Review of the Role of Definitive Local Treatment in Patients with Clinically Lymph Node-positive Prostate Cancer.
  European urology oncology 2019 Ventimiglia E, Seisen T, Abdollah F, Briganti A, Fonteyne V, James N, Roach M, Thalmann GN, Touijer K, Chen RC, Cheng L
• Genomic Risk Predicts Molecular Imaging-detected Metastatic Nodal Disease in Prostate Cancer.
  European urology oncology 2019 Xu MJ, Kornberg Z, Gadzinski AJ, Diao D, Cowan JE, Wu SY, Boreta L, Spratt DE, Behr SC, Nguyen HG, Cooperberg MR, Davicioni E, Roach M, Hope TA, Carroll PR, Feng FY
• Surgery Versus Radiation for High-risk Prostate Cancer: The Fight Continues. But Is It Time To Call a Draw and Reach Consensus?
  European urology 2019 Sooriakumaran P, Pavan N, Wiklund PN, Roach M
• Impact of Staging 68Ga-PSMA-11 PET Scans on Radiation Treatment Plansin Patients With Prostate Cancer.
  Urology 2018 Wu SY, Boreta L, Shinohara K, Nguyen H, Gottschalk AR, Hsu IC, Roach M, Westphalen AC, Feng FY, Carroll PR, Chang AJ, Hope TA
• Clinical trials involving carbon-ion radiation therapy and the path forward.
  Cancer 2018 Lazar AA, Schulte R, Faddegon B, Blakely EA, Roach M
• Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial.
  The Lancet. Oncology 2018 Roach M, Moughan J, Lawton CAF, Dicker AP, Zeitzer KL, Gore EM, Kwok Y, Seider MJ, Hsu IC, Hartford AC, Horwitz EM, Yamoah K, Jones CU, Michalski JM, Lee WR, Pisansky TM, Rabinovitch R, Rotman M, …
• A Prospective Phase 2 Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Cancer After External Beam Radiation Therapy (NRG Oncology/RTOG-0526).
  International journal of radiation oncology, biology, physics 2018 Crook JM, Zhang P, Pisansky TM, Trabulsi EJ, Amin MB, Bice W, Morton G, Pervez N, Vigneault E, Catton C, Michalski J, Roach M, Beyer D, Jani A, Horwitz E, Donavanik V, Sandler H
• Patient Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer.
  International journal of radiation oncology, biology, physics 2018 Lukka HR, Pugh SL, Bruner DW, Bahary JP, Lawton CAF, Efstathiou JA, Kudchadker RJ, Ponsky LE, Seaward SA, Dayes IS, Gopaul DD, Michalski JM, Delouya G, Kaplan ID, Horwitz EM, Roach M, Pinover WH, …
• Risk factors for late bowel and bladder toxicities in NRG Oncology prostate cancer trials of high-risk patients: A meta-analysis of physician-rated toxicities.
  Advances in radiation oncology 2018 Xiao C, Moughan J, Movsas B, Konski AA, Hanks GE, Cox JD, Roach M, Zeitzer KL, Lawton CA, Peters CA, Rosenthal SA, Hsu IJ, Horwitz EM, Mishra MV, Michalski JM, Parliament MB, D'Souza DP, Pugh SL, …
• Optimizing Imperfect Patient Management Recommendations Post-prostatectomy.
  European urology oncology 2018 Roach M, Lazar AA
• Re: Morbidity and Mortality of Locally Advanced Prostate Cancer: A Population Based Analysis Comparing Radical Prostatectomy Versus External Beam Radiation.
  European urology 2017 Roach M
• Stereotactic body radiation therapy (SBRT) for high-risk prostate cancer: Where are we now?
  Practical radiation oncology 2017 Gonzalez-Motta A, Roach M
• Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.
  European urology 2017 Gillessen S, Attard G, Beer TM, Beltran H, Bossi A, Bristow R, Carver B, Castellano D, Chung BH, Clarke N, Daugaard G, Davis ID, de Bono J, Borges Dos Reis R, Drake CG, Eeles R, Efstathiou E, Evans CP…
• Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology RTOG 9202.
  International journal of radiation oncology, biology, physics 2017 Lawton CAF, Lin X, Hanks GE, Lepor H, Grignon DJ, Brereton HD, Bedi M, Rosenthal SA, Zeitzer KL, Venkatesan VM, Horwitz EM, Pisansky TM, Kim H, Parliament MB, Rabinovitch R, Roach M, Kwok Y, Dignam JJ…
• Adjuvant and Salvage Radiotherapy after Radical Prostatectomy in Prostate Cancer Patients.
  European urology 2017 Gandaglia G, Briganti A, Clarke N, Karnes RJ, Graefen M, Ost P, Zietman AL, Roach M
• Receiver operating curves and dose-volume analysis of late toxicity with stereotactic body radiation therapy for prostate cancer.
  Practical radiation oncology 2016 Zhang L, Johnson J, Gottschalk AR, Chang AJ, Hsu IC, Roach M, Seymour ZA
• Interfraction Anatomical Variability Can Lead to Significantly Increased Rectal Dose for Patients Undergoing Stereotactic Body Radiotherapy for Prostate Cancer.
  Technology in cancer research & treatment 2016 Wahl M, Descovich M, Shugard E, Pinnaduwage D, Sudhyadhom A, Chang A, Roach M, Gottschalk A, Chen J
• Prostate cancer: Combining endocrine treatment and radiotherapy: a bright future.
  Nature reviews. Urology 2016 Roach M
• Surgery Provides Better Oncologic Outcomes than Radiation for the Treatment of Prostate Cancer.
  The Journal of urology 2016 Roach M
• Long-term Outcomes Following Radiation Therapy For Prostate Cancer Patients With Lymph Node Metastases at Diagnosis Treated With and Without Surgery.
  American journal of clinical oncology 2016 Crehange G, Izaguirre A, Weinberg V, Hsu CC, Gottschalk AR, Hsu IC, Shinohara K, Carroll P, Roach M
• An Evaluation of Robotic and Conventional IMRT for Prostate Cancer: Potential for Dose Escalation.
  Technology in cancer research & treatment 2016 Pinnaduwage DS, Descovich M, Lometti MW, Varad B, Roach M, Gottschalk AR
• Words of Wisdom. Re: Genomic Classifier Identifies Men with Adverse Pathology After Radical Prostatectomy Who Benefit from Adjuvant Radiation Therapy.
  European urology 2016 Chan J, Roach M
• Re: Christopher J.D. Wallis, Refik Saskin, Richard Choo, et al. Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol 2016;70:21-30: Radical Prostatectomy Versus Radiation for Clinically Localized Prostate Cancer: Two Systematic Reviews and a Randomized Controlled Trial.
  European urology 2016 Lazar AA, Lizarraga TLC, Roach M
• Outcomes of hypofractionated stereotactic body radiotherapy boost for intermediate and high-risk prostate cancer.
  Radiation oncology (London, England) 2016 Anwar M, Weinberg V, Seymour Z, Hsu IJ, Roach M, Gottschalk AR
• New Clinical and Research Programs in Particle Beam Radiation Therapy: The University of California San Francisco Perspective.
  International journal of particle therapy 2016 Roach M, Schulte R, Mishra K, Faddegon B, Barani I, Lazar A, Blakely EA
• Prostate Cancer, Version 1.2016.
  Journal of the National Comprehensive Cancer Network : JNCCN 2016 Mohler JL, Armstrong AJ, Bahnson RR, D'Amico AV, Davis BJ, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Hurwitz M, Kane CJ, Kawachi MH, Kuettel M, Lee RJ, Meeks JJ, Penson DF, Plimack ER…
• Sentinel lymph node imaging guided IMRT for prostate cancer: Individualized pelvic radiation therapy versus RTOG guidelines.
  Advances in radiation oncology 2015 Chen CP, Johnson J, Seo Y, Weinberg VK, Shinohara K, Hsu IJ, Roach M
• Radical Prostatectomy Versus Radiation and Androgen Deprivation Therapy for Clinically Localized Prostate Cancer: How Good Is the Evidence?
  International journal of radiation oncology, biology, physics 2015 Roach M, Ceron Lizarraga TL, Lazar AA
• Knowledge and attitudes regarding clinical trials and willingness to participate among prostate cancer patients.
  Contemporary clinical trials 2015 Kaplan CP, Nápoles AM, Narine S, Gregorich S, Livaudais-Toman J, Nguyen T, Leykin Y, Roach M, Small EJ
• Patient- and treatment-specific predictors of genitourinary function after high-dose-rate monotherapy for favorable prostate cancer.
  Brachytherapy 2015 Raleigh DR, Chang AJ, Tomlin B, Cunha JA, Braunstein SE, Shinohara K, Gottschalk AR, Roach M, Hsu IC
• Reporting of results in DART01/05 GICOR.
  The Lancet. Oncology 2015 Pisansky TM, Suman VJ, Roach M, Sandler HM
• Postoperative radiation therapy for patients at high-risk of recurrence after radical prostatectomy: does timing matter?
  BJU international 2015 Hsu CC, Paciorek AT, Cooperberg MR, Roach M, Hsu IC, Carroll PR
• Patterns of Local Failure following Radiation Therapy for Prostate Cancer.
  The Journal of urology 2015 Jalloh M, Leapman MS, Cowan JE, Shinohara K, Greene KL, Roach M, Chang AJ, Chan JM, Simko JP, Carroll PR
• Postprostatectomy Radiotherapy for Patients with High-risk Features on Definitive Pathology: A Plea for Evidence-based Medicine.
  European urology 2015 Bossi A, Wiegel T, Roach M
• Dose-volume analysis and the temporal nature of toxicity with stereotactic body radiation therapy for prostate cancer.
  Practical radiation oncology 2015 Seymour ZA, Chang AJ, Zhang L, Kirby N, Descovich M, Roach M, Hsu IC, Gottschalk AR
• Bladder wall recurrence of prostate cancer after high-dose-rate brachytherapy.
  Brachytherapy 2014 Raleigh DR, Hsu IC, Braunstein S, Chang AJ, Simko JP, Roach M
• Impact of biochemical failure classification on clinical outcome: a secondary analysis of Radiation Therapy Oncology Group 9202 and 9413.
  Cancer 2014 Hamstra DA, Bae K, Hanks G, Hu C, Shipley WU, Pan CC, Roach M, Lawton CA, Sandler HM
• Natural History after Biochemical Failure Following Dose-escalated External Beam Radiation: An Opportunity to Improve Outcomes?
  European urology 2014 Roach M
• Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature.
  European urology 2014 Ost P, Bossi A, Decaestecker K, De Meerleer G, Giannarini G, Karnes RJ, Roach M, Briganti A
• Pre-plan parameters predict post-implant D90 ≥ 140 Gy for (125)I permanent prostate implants.
  Journal of contemporary brachytherapy 2014 Alexander J, Weinberg V, Gottschalk AR, Hsu IC, Shinohara K, Roach M
• Quality improvement of International Classification of Diseases, 9th revision, diagnosis coding in radiation oncology: single-institution prospective study at University of California, San Francisco.
  Practical radiation oncology 2014 Chen CP, Braunstein S, Mourad M, Hsu IC, Haas-Kogan D, Roach M, Fogh SE
• High-risk prostate cancer-classification and therapy.
  Nature reviews. Clinical oncology 2014 Chang AJ, Autio KA, Roach M, Scher HI
• Prostate cancer, version 2.2014.
  Journal of the National Comprehensive Cancer Network : JNCCN 2014 Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Kane CJ, Kawachi MH, Kuettel M, Kuzel TM, Lee RJ, Malcolm AW, Miller D,…
• Radium-223 vs EBRT for multiple painful bone metastases: is less more?
  Oncology (Williston Park, N.Y.) 2014 Roach M
• Radical prostatectomy v radiation: only a randomised trial can provide the answer.
  BMJ (Clinical research ed.) 2014 Roach M
• Prostate cancer: impact of national guidelines on brachytherapy monotherapy.
  Nature reviews. Urology 2014 Johnson J, Roach M
• Current trends for the use of androgen deprivation therapy in conjunction with radiotherapy for patients with unfavorable intermediate-risk, high-risk, localized, and locally advanced prostate cancer.
  Cancer 2014 Roach M
• Endoscopic gold fiducial marker placement into the bladder wall to optimize radiotherapy targeting for bladder-preserving management of muscle-invasive bladder cancer: feasibility and initial outcomes.
  PloS one 2014 Garcia MM, Gottschalk AR, Brajtbord J, Konety BR, Meng MV, Roach M, Carroll PR
• Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: comparison of PSA slope and nadir.
  Radiation oncology (London, England) 2014 Anwar M, Weinberg V, Chang AJ, Hsu IC, Roach M, Gottschalk A
• Offline multiple adaptive planning strategy for concurrent irradiation of the prostate and pelvic lymph nodes.
  Medical physics 2014 Qi P, Pouliot J, Roach M, Xia P
• Role of endorectal MR imaging and MR spectroscopic imaging in defining treatable intraprostatic tumor foci in prostate cancer: quantitative analysis of imaging contour compared to whole-mount histopathology.
  Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2014 Anwar M, Westphalen AC, Jung AJ, Noworolski SM, Simko JP, Kurhanewicz J, Roach M, Carroll PR, Coakley FV
• Prostate cancer, version 1.2014.
  Journal of the National Comprehensive Cancer Network : JNCCN 2013 Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Kawachi MH, Kuettel M, Lee RJ, Macvicar GR, Malcolm AW, Miller D, …
• Cold spot mapping inferred from MRI at time of failure predicts biopsy-proven local failure after permanent seed brachytherapy in prostate cancer patients: implications for focal salvage brachytherapy.
  Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2013 Crehange G, Krishnamurthy D, Cunha JA, Pickett B, Kurhanewicz J, Hsu IC, Gottschalk AR, Shinohara K, Roach M, Pouliot J
• Improving plan quality and consistency by standardization of dose constraints in prostate cancer patients treated with CyberKnife.
  Journal of applied clinical medical physics 2013 Descovich M, Carrara M, Morlino S, Pinnaduwage DS, Saltiel D, Pouliot J, Nash MB, Pignoli E, Valdagni R, Roach M, Gottschalk AR
• Early salvage radiotherapy following radical prostatectomy.
  European urology 2013 Pfister D, Bolla M, Briganti A, Carroll P, Cozzarini C, Joniau S, van Poppel H, Roach M, Stephenson A, Wiegel T, Zelefsky MJ
• Adjuvant and salvage radiation therapy after prostatectomy: American Society for Radiation Oncology/American Urological Association guidelines.
  International journal of radiation oncology, biology, physics 2013 Valicenti RK, Thompson I, Albertsen P, Davis BJ, Goldenberg SL, Wolf JS, Sartor O, Klein E, Hahn C, Michalski J, Roach M, Faraday MM, American Society for Radiation Oncology/American Urological …
• Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline.
  The Journal of urology 2013 Thompson IM, Valicenti RK, Albertsen P, Davis BJ, Goldenberg SL, Hahn C, Klein E, Michalski J, Roach M, Sartor O, Wolf JS, Faraday MM
• Vascular endothelial growth factor (VEGF) expression in locally advanced prostate cancer: secondary analysis of radiation therapy oncology group (RTOG) 8610.
  Radiation oncology (London, England) 2013 Pan L, Baek S, Edmonds PR, Roach M, Wolkov H, Shah S, Pollack A, Hammond ME, Dicker AP
• Whole-pelvic nodal radiation therapy in the context of hypofractionation for high-risk prostate cancer patients: a step forward.
  International journal of radiation oncology, biology, physics 2013 Kaidar-Person O, Roach M, Créhange G
• Prostate-specific antigen response after short-term hormone therapy plus external-beam radiotherapy and outcome in patients treated on Radiation Therapy Oncology Group study 9413.
  Cancer 2013 Cury FL, Hunt D, Roach M, Shipley W, Gore E, Hsu IC, Krisch RE, Seider MJ, Sandler H, Lawton C
• Salvage HDR brachytherapy for recurrent prostate cancer after previous definitive radiation therapy: 5-year outcomes.
  International journal of radiation oncology, biology, physics 2013 Chen CP, Weinberg V, Shinohara K, Roach M, Nash M, Gottschalk A, Chang AJ, Hsu IC
• Cautious optimism for extreme dose escalation in prostate cancer.
  European urology 2013 Chang AJ, Roach M
• Computer-assisted, atlas-based segmentation for target volume delineation in whole pelvic IMRT for prostate cancer.
  Technology in cancer research & treatment 2012 Pejavar S, Yom SS, Hwang A, Speight J, Gottschalk A, Hsu IC, Roach M, Xia P
• Overview of randomized controlled treatment trials for clinically localized prostate cancer: implications for active surveillance and the United States preventative task force report on screening?
  Journal of the National Cancer Institute. Monographs 2012 Roach M, Thomas K
• Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines.
  Journal of the National Comprehensive Cancer Network : JNCCN 2012 Mohler JL, Armstrong AJ, Bahnson RR, Boston B, Busby JE, D'Amico AV, Eastham JA, Enke CA, Farrington T, Higano CS, Horwitz EM, Kantoff PW, Kawachi MH, Kuettel M, Lee RJ, MacVicar GR, Malcolm AW, …
• Clinical outcome of patients treated with 3D conformal radiation therapy (3D-CRT) for prostate cancer on RTOG 9406.
  International journal of radiation oncology, biology, physics 2012 Michalski J, Winter K, Roach M, Markoe A, Sandler HM, Ryu J, Parliament M, Purdy JA, Valicenti RK, Cox JD
• Management of prostate cancer patients with lymph node involvement: a rapidly evolving paradigm.
  Cancer treatment reviews 2012 Créhange G, Chen CP, Hsu CC, Kased N, Coakley FV, Kurhanewicz J, Roach M
• Feasibility of MR imaging/MR spectroscopy-planned focal partial salvage permanent prostate implant (PPI) for localized recurrence after initial PPI for prostate cancer.
  International journal of radiation oncology, biology, physics 2012 Hsu CC, Hsu H, Pickett B, Crehange G, Hsu IC, Dea R, Weinberg V, Gottschalk AR, Kurhanewicz J, Shinohara K, Roach M
• Magnetic resonance lymphography findings in patients with biochemical recurrence after prostatectomy and the relation with the Stephenson nomogram.
  International journal of radiation oncology, biology, physics 2012 Meijer HJ, Debats OA, Roach M, Span PN, Witjes JA, Kaanders JH, van Lin EN, Barentsz JO
• Radium-223: down to the bone, and less is more.
  Oncology (Williston Park, N.Y.) 2012 Chang AJ, Roach M
• High-risk prostate cancer: from definition to contemporary management.
  European urology 2012 Bastian PJ, Boorjian SA, Bossi A, Briganti A, Heidenreich A, Freedland SJ, Montorsi F, Roach M, Schröder F, van Poppel H, Stief CG, Stephenson AJ, Zelefsky MJ
• Long-term potency preservation following brachytherapy for prostate cancer.
  BJU international 2012 Roach M
• Does local recurrence of prostate cancer after radiation therapy occur at the site of primary tumor? Results of a longitudinal MRI and MRSI study.
  International journal of radiation oncology, biology, physics 2012 Arrayeh E, Westphalen AC, Kurhanewicz J, Roach M, Jung AJ, Carroll PR, Coakley FV
• Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group.
  BJU international 2012 Grimm P, Billiet I, Bostwick D, Dicker AP, Frank S, Immerzeel J, Keyes M, Kupelian P, Lee WR, Machtens S, Mayadev J, Moran BJ, Merrick G, Millar J, Roach M, Stock R, Shinohara K, Scholz M, Weber E, …
• Irradiation of the prostate and pelvic lymph nodes with an adaptive algorithm.
  Medical physics 2012 Hwang AB, Chen J, Nguyen TB, Gottschalk AG, Roach MR, Pouliot J
• A treatment planning and acute toxicity comparison of two pelvic nodal volume delineation techniques and delivery comparison of intensity-modulated radiotherapy versus volumetric modulated arc therapy for hypofractionated high-risk prostate cancer radiotherapy.
  International journal of radiation oncology, biology, physics 2012 Myrehaug S, Chan G, Craig T, Weinberg V, Cheng C, Roach M, Cheung P, Sahgal A
• Editorial comment.
  Urology 2011 Roach M
• Temporal compartmental dosing effects for robotic prostate stereotactic body radiotherapy.
  Physics in medicine and biology 2011 Shiao SL, Sahgal A, Hu W, Jabbari S, Chuang C, Descovich M, Hsu IC, Gottschalk AR, Roach M, Ma L
• Indications and practice with androgen deprivation therapy.
  Urology 2011 Moul JW, Kibel AS, Roach M, Dreicer R
• Traditional approaches to androgen deprivation therapy.
  Urology 2011 Moul JW, Evans CP, Gomella LG, Roach M, Dreicer R
• Postoperative radiation therapy for pathologically advanced prostate cancer after radical prostatectomy.
  European urology 2011 Stephenson AJ, Bolla M, Briganti A, Cozzarini C, Moul JW, Roach M, van Poppel H, Zietman A
• Urethra low-dose tunnels: validation of and class solution for generating urethra-sparing dose plans using inverse planning simulated annealing for prostate high-dose-rate brachytherapy.
  Brachytherapy 2011 Cunha JA, Pouliot J, Weinberg V, Wang-Chesebro A, Roach M, Hsu IC
• Validation of a Predictive Model for Survival in Patients With Advanced Cancer: Secondary Analysis of RTOG 9714.
  World journal of oncology 2011 Chow E, James JL, Hartsell W, Scarantino CW, Ivker R, Roach M, Suh JH, Demas W, Konski A, Bruner DW
• Promoting wellness for patients on androgen deprivation therapy: why using numerous drugs for drug side effects should not be first-line treatment.
  The Urologic clinics of North America 2011 Moyad MA, Roach M
• Benefits and pitfalls of prostate cancer screening: "no proof of benefit" does not equal "proof of no benefit".
  Oncology (Williston Park, N.Y.) 2011 Chen CP, Staggers FE, Roach M
• Diagnostic and therapeutic imaging for cancer: therapeutic considerations and future directions.
  Journal of surgical oncology 2011 Roach M, Alberini JL, Pecking AP, Testori A, Verrecchia F, Soteldo J, Ganswindt U, Joyal JL, Babich JW, Witte RS, Unger E, Gottlieb R
• Endorectal MRI after radiation therapy: questioning the sextant analysis.
  Journal of magnetic resonance imaging : JMRI 2011 Kumbhani SR, Coakley FV, McCulloch CE, Wang ZJ, Kurhanewicz J, Roach M, Westphalen AC
• Pelvic nodal radiotherapy in patients with unfavorable intermediate and high-risk prostate cancer: evidence, rationale, and future directions.
  International journal of radiation oncology, biology, physics 2011 Morikawa LK, Roach M
• Editorial comment.
  Urology 2011 Roach M
• Predicting the risk of pelvic node involvement in men with prostate cancer in the contemporary era: change you can believe?: in regard to Yu, et al. (Int J Radiat Oncol Biol Phys in press).
  International journal of radiation oncology, biology, physics 2011 Hayes M, Roach M
• Older age predicts decreased metastasis and prostate cancer-specific death for men treated with radiation therapy: meta-analysis of radiation therapy oncology group trials.
  International journal of radiation oncology, biology, physics 2011 Hamstra DA, Bae K, Pilepich MV, Hanks GE, Grignon DJ, McGowan DG, Roach M, Lawton C, Lee RJ, Sandler H
• Successful radiation treatment of anaplastic thyroid carcinoma metastatic to the right cardiac atrium and ventricle in a pacemaker-dependent patient.
  Radiation oncology (London, England) 2011 Dasgupta T, Barani IJ, Roach M
• Editorial comment.
  BJU international 2011 Roach M
• Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response.
  International journal of radiation oncology, biology, physics 2010 Jabbari S, Weinberg VK, Kaprealian T, Hsu IC, Ma L, Chuang C, Descovich M, Shiao S, Shinohara K, Roach M, Gottschalk AR
• High-dose-rate brachytherapy boost for prostate cancer: comparison of two different fractionation schemes.
  International journal of radiation oncology, biology, physics 2010 Kaprealian T, Weinberg V, Speight JL, Gottschalk AR, Roach M, Shinohara K, Hsu IC
• Comparison of three strategies in management of independent movement of the prostate and pelvic lymph nodes.
  Medical physics 2010 Xia P, Qi P, Hwang A, Kinsey E, Pouliot J, Roach M
• Primary focal unilateral nerve-sparing cryoablation for very early prostate cancer: is it enough or too much, or do we know?
  Cancer journal (Sudbury, Mass.) 2010 Roach M
• Impact of ultrahigh baseline PSA levels on biochemical and clinical outcomes in two Radiation Therapy Oncology Group prostate clinical trials.
  International journal of radiation oncology, biology, physics 2010 Rodrigues G, Bae K, Roach M, Lawton C, Donnelly B, Grignon D, Hanks G, Porter A, Lepor H, Sandler H
• Do not count out external-beam radiation therapy for high-risk prostate cancer.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010 Hamstra DA, Michalski JM, Roach M, Sandler HM
• Who, when, where, and how: salvage prostate cancer with radiotherapy.
  Oncology (Williston Park, N.Y.) 2010 Chien CP, Roach M
• Locally recurrent prostate cancer after external beam radiation therapy: diagnostic performance of 1.5-T endorectal MR imaging and MR spectroscopic imaging for detection.
  Radiology 2010 Westphalen AC, Coakley FV, Roach M, McCulloch CE, Kurhanewicz J
• Baseline serum testosterone in men treated with androgen deprivation therapy and radiotherapy for localized prostate cancer.
  International journal of radiation oncology, biology, physics 2010 Roach M, Bae K, Lawton C, Donnelly BJ, Grignon D, Hanks GE, Porter A, Lepor H, Venketesan V, Sandler H
• Prostate cancer: worse sexual function after cryoablation--a case for EBRT?
  Nature reviews. Urology 2010 Roach M
• Radiation dose-volume effects and the penile bulb.
  International journal of radiation oncology, biology, physics 2010 Roach M, Nam J, Gagliardi G, El Naqa I, Deasy JO, Marks LB
• Dose gradient near target-normal structure interface for nonisocentric CyberKnife and isocentric intensity-modulated body radiotherapy for prostate cancer.
  International journal of radiation oncology, biology, physics 2010 Hossain S, Xia P, Huang K, Descovich M, Chuang C, Gottschalk AR, Roach M, Ma L
• NCCN clinical practice guidelines in oncology: prostate cancer.
  Journal of the National Comprehensive Cancer Network : JNCCN 2010 Mohler J, Bahnson RR, Boston B, Busby JE, D'Amico A, Eastham JA, Enke CA, George D, Horwitz EM, Huben RP, Kantoff P, Kawachi M, Kuettel M, Lange PH, Macvicar G, Plimack ER, Pow-Sang JM, Roach M, …
• Equivalent biochemical control and improved prostate-specific antigen nadir after permanent prostate seed implant brachytherapy versus high-dose three-dimensional conformal radiotherapy and high-dose conformal proton beam radiotherapy boost.
  International journal of radiation oncology, biology, physics 2010 Jabbari S, Weinberg VK, Shinohara K, Speight JL, Gottschalk AR, Hsu IC, Pickett B, McLaughlin PW, Sandler HM, Roach M
• Long-term toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG 9406 phase I/II dose escalation study.
  International journal of radiation oncology, biology, physics 2010 Michalski JM, Bae K, Roach M, Markoe AM, Sandler HM, Ryu J, Parliament MB, Straube W, Valicenti RK, Cox JD
• Editorial comment.
  The Journal of urology 2009 Roach M
• Predicting the risk of pelvic node involvement among men with prostate cancer in the contemporary era: change you can believe in, or back to the future? (In regard to Nguyen PL, et al. (Int J Radiat Oncol Biol Phys 2009).
  International journal of radiation oncology, biology, physics 2009 Roach M
• Economic analysis of radiation therapy oncology group 97-14: multiple versus single fraction radiation treatment of patients with bone metastases.
  American journal of clinical oncology 2009 Konski A, James J, Hartsell W, Leibenhaut MH, Janjan N, Curran W, Roach M, Watkins-Bruner D
• Functional interference clusters in cancer patients with bone metastases: a secondary analysis of RTOG 9714.
  International journal of radiation oncology, biology, physics 2009 Chow E, James J, Barsevick A, Hartsell W, Ratcliffe S, Scarantino C, Ivker R, Roach M, Suh J, Petersen I, Konski A, Demas W, Bruner D
• Predictive models in external beam radiotherapy for clinically localized prostate cancer.
  Cancer 2009 Roach M, Waldman F, Pollack A
• Postoperative nomogram predicting the 9-year probability of prostate cancer recurrence after permanent prostate brachytherapy using radiation dose as a prognostic variable.
  International journal of radiation oncology, biology, physics 2009 Potters L, Roach M, Davis BJ, Stock RG, Ciezki JP, Zelefsky MJ, Stone NN, Fearn PA, Yu C, Shinohara K, Kattan MW
• High-dose-rate brachytherapy for localized prostate adenocarcinoma post abdominoperineal resection of the rectum and pelvic irradiation: Technique and experience.
  Brachytherapy 2009 Jabbari S, Hsu IC, Kawakami J, Weinberg VK, Speight JL, Gottschalk AR, Roach M, Shinohara K
• ACR appropriateness criteria on external beam radiation therapy treatment planning for clinically localized prostate cancer expert panel on radiation oncology--prostate.
  International journal of radiation oncology, biology, physics 2009 Michalski JM, Roach M, Merrick G, Anscher MS, Beyer DC, Lawton CA, Lee WR, Pollack A, Rosenthal SA, Vijayakumar S, Carroll PR
• Salvage permanent perineal radioactive-seed implantation for treating recurrence of localized prostate adenocarcinoma after external beam radiotherapy.
  BJU international 2009 Aaronson DS, Yamasaki I, Gottschalk A, Speight J, Hsu IC, Pickett B, Roach M, Shinohara K
• Predicting pathologic stage, nomograms, and clinical judgment: don't miss the forest for the trees!
  International journal of radiation oncology, biology, physics 2009 Roach M
• Clinical decisions. Management of prostate cancer.
  The New England journal of medicine 2008 Schröder FH, Roach M, Scardino P
• Variation in the definition of clinical target volumes for pelvic nodal conformal radiation therapy for prostate cancer.
  International journal of radiation oncology, biology, physics 2008 Lawton CA, Michalski J, El-Naqa I, Kuban D, Lee WR, Rosenthal SA, Zietman A, Sandler H, Shipley W, Ritter M, Valicenti R, Catton C, Roach M, Pisansky TM, Seider M
• Comparison of dosimetric and biologic effective dose parameters for prostate and urethra using 131 Cs and 125 I for prostate permanent implant brachytherapy.
  International journal of radiation oncology, biology, physics 2008 Sahgal A, Jabbari S, Chen J, Pickett B, Roach M, Weinberg V, Hsu IC, Pouliot J
• Pretreatment endorectal magnetic resonance imaging and magnetic resonance spectroscopic imaging features of prostate cancer as predictors of response to external beam radiotherapy.
  International journal of radiation oncology, biology, physics 2008 Joseph T, McKenna DA, Westphalen AC, Coakley FV, Zhao S, Lu Y, Hsu IC, Roach M, Kurhanewicz J
• Targeting pelvic lymph nodes in men with intermediate- and high-risk prostate cancer, and confusion about the results of the randomized trials.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008 Roach M
• Quality of life and satisfaction with outcome among prostate-cancer survivors.
  The New England journal of medicine 2008 Yu JS, Roach M
• Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy.
  International journal of radiation oncology, biology, physics 2008 Stone NN, Potters L, Davis BJ, Ciezki JP, Zelefsky MJ, Roach M, Shinohara K, Fearn PA, Kattan MW, Stock RG
• "Short- and long-term mortality with localized prostate cancer": errors and omissions?
  Archives of internal medicine 2008 Roach M
• Can physicians accurately predict survival time in patients with metastatic cancer? Analysis of RTOG 97-14.
  Journal of palliative medicine 2008 Hartsell WF, Desilvio M, Bruner DW, Scarantino C, Ivker R, Roach M, Suh J, Demas WF, Movsas B, Petersen IA, Konski AA
• Does image-guided radiotherapy improve toxicity profile in whole pelvic-treated high-risk prostate cancer? Comparison between IG-IMRT and IMRT.
  International journal of radiation oncology, biology, physics 2008 Chung HT, Xia P, Chan LW, Park-Somers E, Roach M
• Proposed rectal dose constraints for patients undergoing definitive whole pelvic radiotherapy for clinically localized prostate cancer.
  International journal of radiation oncology, biology, physics 2008 Chan LW, Xia P, Gottschalk AR, Akazawa M, Scala M, Pickett B, Hsu IC, Speight J, Roach M
• Does timing of androgen deprivation influence radiation-induced toxicity? A secondary analysis of radiation therapy oncology group protocol 9413.
  Urology 2008 Taussky D, Bae K, Bahary JP, Roach M, Lawton CA, Shipley WU, Sandler HM
• Assessment of external beam radiation technology for dose escalation and normal tissue protection in the treatment of prostate cancer.
  International journal of radiation oncology, biology, physics 2008 D'Ambrosio DJ, Pollack A, Harris EE, Price RA, Verhey LJ, Roach M, Demanes DJ, Steinberg ML, Potters L, Wallner PE, Konski A
• Prostate cancer: role of pretreatment MR in predicting outcome after external-beam radiation therapy--initial experience.
  Radiology 2008 McKenna DA, Coakley FV, Westphalen AC, Zhao S, Lu Y, Webb EM, Pickett B, Roach M, Kurhanewicz J
• Technique for implantation of fiducial markers in the prostate.
  Urology 2008 Shinohara K, Roach M
• Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008 Roach M, Bae K, Speight J, Wolkov HB, Rubin P, Lee RJ, Lawton C, Valicenti R, Grignon D, Pilepich MV
• Are lateral electronic portal images adequate for accurate on-line daily targeting of the prostate? Results of a prospective study.
  Medical dosimetry : official journal of the American Association of Medical Dosimetrists 2008 Lometti MW, Thurston D, Aubin M, Bock A, Verhey L, Lockhart JM, Bland R, Pouliot J, Roach M
• An algorithm for shifting MLC shapes to adjust for daily prostate movement during concurrent treatment with pelvic lymph nodes.
  Medical physics 2007 Ludlum E, Mu G, Weinberg V, Roach M, Verhey LJ, Xia P
• Dose escalated external beam radiotherapy versus neoadjuvant androgen deprivation therapy and conventional dose external beam radiotherapy for clinically localized prostate cancer: do we need both?
  Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] 2007 Roach M
• Permanent prostate seed brachytherapy: a current perspective on the evolution of the technique and its application.
  Nature clinical practice. Urology 2007 Sahgal A, Roach M
• Regarding the influence of adjuvant suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarction: how real is the risk?
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007 Roach M
• Editorial comment on: high provider volume is associated with lower rate of secondary therapies after definitive radiotherapy for localized prostate cancer.
  European urology 2007 Roach M
• Customized dose prescription for permanent prostate brachytherapy: insights from a multicenter analysis of dosimetry outcomes.
  International journal of radiation oncology, biology, physics 2007 Stone NN, Potters L, Davis BJ, Ciezki JP, Zelefsky MJ, Roach M, Fearn PA, Kattan MW, Stock RG
• Prostate cancer. Clinical practice guidelines in oncology.
  Journal of the National Comprehensive Cancer Network : JNCCN 2007 Mohler J, Babaian RJ, Bahnson RR, Boston B, D'Amico A, Eastham JA, Hauke RJ, Huben RP, Kantoff P, Kawachi M, Kuettel M, Lange PH, Logothetis C, MacVicar G, Pollack A, Pow-Sang JM, Roach M, Sandler H, …
• Current role and future perspectives of magnetic resonance spectroscopy in radiation oncology for prostate cancer.
  Neoplasia (New York, N.Y.) 2007 Zapotoczna A, Sasso G, Simpson J, Roach M
• An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions.
  International journal of radiation oncology, biology, physics 2007 Lawton CA, DeSilvio M, Roach M, Uhl V, Kirsch R, Seider M, Rotman M, Jones C, Asbell S, Valicenti R, Hahn S, Thomas CR
• Positional stability of electromagnetic transponders used for prostate localization and continuous, real-time tracking.
  International journal of radiation oncology, biology, physics 2007 Litzenberg DW, Willoughby TR, Balter JM, Sandler HM, Wei J, Kupelian PA, Cunningham AA, Bock A, Aubin M, Roach M, Shinohara K, Pouliot J
• Racial differences in CYP3A4 genotype and survival among men treated on Radiation Therapy Oncology Group (RTOG) 9202: a phase III randomized trial.
  International journal of radiation oncology, biology, physics 2007 Roach M, De Silvio M, Rebbick T, Grignon D, Rotman M, Wolkov H, Fisher B, Hanks G, Shipley WU, Pollack A, Sandler H, Watkins-Bruner D
• Advances in the treatment of localized prostate cancer: the role of anatomic and functional imaging in men managed with radiotherapy.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007 Speight JL, Roach M
• Daily electronic portal imaging of implanted gold seed fiducials in patients undergoing radiotherapy after radical prostatectomy.
  International journal of radiation oncology, biology, physics 2007 Schiffner DC, Gottschalk AR, Lometti M, Aubin M, Pouliot J, Speight J, Hsu IC, Shinohara K, Roach M
• Goserelin acetate in combination with radiotherapy for prostate cancer.
  Expert opinion on pharmacotherapy 2007 Roach M, Izaguirre A
• State-of-the-art radiotherapy in the management of clinically localized prostate carcinoma.
  Future oncology (London, England) 2007 Bermudez RS, Izaguirre A, Roach M
• Staging for prostate cancer: time to incorporate pretreatment prostate-specific antigen and Gleason score?
  Cancer 2007 Roach M, Weinberg V, Sandler H, Thompson I
• Interstitial implant alone or in combination with external beam radiation therapy for intermediate-risk prostate cancer: a survey of practice patterns in the United States.
  Brachytherapy 2007 Frank SJ, Grimm PD, Sylvester JE, Merrick GS, Davis BJ, Zietman A, Moran BJ, Beyer DC, Roach M, Clarke DH, Stock RG, Robert Lee W, Michalski JM, Wallner KE, Hurwitz M, Potters L, Kuban DA, Prestidge …
• Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California-San Francisco experience.
  International journal of radiation oncology, biology, physics 2006 Lee B, Shinohara K, Weinberg V, Gottschalk AR, Pouliot J, Roach M, Hsu IC
• Defining high risk prostate cancer with risk groups and nomograms: implications for designing clinical trials.
  The Journal of urology 2006 Roach M, Weinberg V, Nash M, Sandler HM, McLaughlin PW, Kattan MW
• Intensity-modulated radiotherapy improves lymph node coverage and dose to critical structures compared with three-dimensional conformal radiation therapy in clinically localized prostate cancer.
  International journal of radiation oncology, biology, physics 2006 Wang-Chesebro A, Xia P, Coleman J, Akazawa C, Roach M
• Whole-pelvis, "mini-pelvis," or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial.
  International journal of radiation oncology, biology, physics 2006 Roach M, DeSilvio M, Valicenti R, Grignon D, Asbell SO, Lawton C, Thomas CR, Shipley WU
• Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference.
  International journal of radiation oncology, biology, physics 2006 Roach M, Hanks G, Thames H, Schellhammer P, Shipley WU, Sokol GH, Sandler H
• Target localization and real-time tracking using the Calypso 4D localization system in patients with localized prostate cancer.
  International journal of radiation oncology, biology, physics 2006 Willoughby TR, Kupelian PA, Pouliot J, Shinohara K, Aubin M, Roach M, Skrumeda LL, Balter JM, Litzenberg DW, Hadley SW, Wei JT, Sandler HM
• Radiotherapy in the management of common genitourinary malignancies.
  Hematology/oncology clinics of North America 2006 Speight JL, Roach M
• Three-dimensional conformal external beam radiotherapy compared with permanent prostate implantation in low-risk prostate cancer based on endorectal magnetic resonance spectroscopy imaging and prostate-specific antigen level.
  International journal of radiation oncology, biology, physics 2006 Pickett B, Kurhanewicz J, Pouliot J, Weinberg V, Shinohara K, Coakley F, Roach M
• Influence of number of CAG repeats on local control in the RTOG 86-10 protocol.
  American journal of clinical oncology 2006 Abdel-Wahab M, Berkey BA, Krishan A, O'Brien T, Hammond E, Roach M, Lawton C, Pilepich M, Markoe A, Pollack A
• Early initiation of salvage hormone therapy influences survival in patients who failed initial radiation for locally advanced prostate cancer: A secondary analysis of RTOG protocol 86-10.
  International journal of radiation oncology, biology, physics 2006 Shipley WU, Desilvio M, Pilepich MV, Roach M, Wolkov HB, Sause WT, Rubin P, Lawton CA
• Megavoltage cone-beam CT: system description and clinical applications.
  Medical dosimetry : official journal of the American Association of Medical Dosimetrists 2006 Morin O, Gillis A, Chen J, Aubin M, Bucci MK, Roach M, Pouliot J
• New techniques and management options for localized prostate cancer.
  Reviews in urology 2006 Speight JL, Roach M
• Prostate cancer progression after therapy of primary curative intent: a review of data from prostate-specific antigen era.
  Cancer 2005 Soloway M, Roach M
• Radiotherapy in the management of clinically localized prostate cancer: evolving standards, consensus, controversies and new directions.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005 Speight JL, Roach M
• Radiotherapy plus adjuvant goserelin improves survival in men with poor prognosis prostate cancer.
  Cancer treatment reviews 2005 Roach M
• Commentary on increased risk of biochemical and local failure in patients with a distended rectum on the planning CT for prostate cancer radiotherapy.
  International journal of radiation oncology, biology, physics 2005 Roach M
• Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V.
  International journal of radiation oncology, biology, physics 2005 Michalski JM, Winter K, Purdy JA, Parliament M, Wong H, Perez CA, Roach M, Bosch W, Cox JD
• Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases.
  Journal of the National Cancer Institute 2005 Hartsell WF, Scott CB, Bruner DW, Scarantino CW, Ivker RA, Roach M, Suh JH, Demas WF, Movsas B, Petersen IA, Konski AA, Cleeland CS, Janjan NA, DeSilvio M
• Evidence-based review of three-dimensional conformal radiotherapy for localized prostate cancer: an ASTRO outcomes initiative.
  International journal of radiation oncology, biology, physics 2005 Morris DE, Emami B, Mauch PM, Konski AA, Tao ML, Ng AK, Klein EA, Mohideen N, Hurwitz MD, Fraas BA, Roach M, Gore EM, Tepper JE
• Advances in radiation therapy: conventional to 3D, to IMRT, to 4D, and beyond.
  CA: a cancer journal for clinicians 2005 Bucci MK, Bevan A, Roach M
• Low-dose megavoltage cone-beam CT for radiation therapy.
  International journal of radiation oncology, biology, physics 2005 Pouliot J, Bani-Hashemi A, Chen J, Svatos M, Ghelmansarai F, Mitschke M, Aubin M, Xia P, Morin O, Bucci K, Roach M, Hernandez P, Zheng Z, Hristov D, Verhey L
• Combined modality treatment with high-dose-rate brachytherapy boost for locally advanced prostate cancer.
  Brachytherapy 2005 Hsu IC, Cabrera AR, Weinberg V, Speight J, Gottschalk AR, Roach M, Shinohara K
• Integrating hormonal therapy with external-beam radiation and brachytherapy for prostate cancer.
  Oncology (Williston Park, N.Y.) 2005 Andrews J, Roach M
• Is it time to change the standard of care from CT to MRI for defining the apex of the prostate to accomplish potency-sparing radiotherapy?
  International journal of radiation oncology, biology, physics 2005 Roach M
• Penile bulb dose and impotence after three-dimensional conformal radiotherapy for prostate cancer on RTOG 9406: findings from a prospective, multi-institutional, phase I/II dose-escalation study.
  International journal of radiation oncology, biology, physics 2004 Roach M, Winter K, Michalski JM, Cox JD, Purdy JA, Bosch W, Lin X, Shipley WS
• Use of MRI and spectroscopy in evaluation of external beam radiotherapy for prostate cancer.
  International journal of radiation oncology, biology, physics 2004 Pickett B, Kurhanewicz J, Coakley F, Shinohara K, Fein B, Roach M
• Prostate movement during simulation resulting from retrograde urethrogram compared with "natural" prostate movement.
  International journal of radiation oncology, biology, physics 2004 Liu YM, Ling S, Langen KM, Shinohara K, Weinberg V, Pouliot J, Roach M
• Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: preliminary experience.
  Radiology 2004 Coakley FV, Teh HS, Qayyum A, Swanson MG, Lu Y, Roach M, Pickett B, Shinohara K, Vigneron DB, Kurhanewicz J
• Changing trends in national practice for external beam radiotherapy for clinically localized prostate cancer: 1999 Patterns of Care survey for prostate cancer.
  International journal of radiation oncology, biology, physics 2004 Zelefsky MJ, Moughan J, Owen J, Zietman AL, Roach M, Hanks GE
• Time to metabolic atrophy after permanent prostate seed implantation based on magnetic resonance spectroscopic imaging.
  International journal of radiation oncology, biology, physics 2004 Pickett B, Ten Haken RK, Kurhanewicz J, Qayyum A, Shinohara K, Fein B, Roach M
• Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy: an analysis of patients in radiation therapy oncology group protocol 86-10.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2004 Li R, Heydon K, Hammond ME, Grignon DJ, Roach M, Wolkov HB, Sandler HM, Shipley WU, Pollack A
• Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004 Pollack A, DeSilvio M, Khor LY, Li R, Al-Saleem TI, Hammond ME, Venkatesan V, Lawton CA, Roach M, Shipley WU, Hanks GE, Sandler HM
• Daily electronic portal imaging for morbidly obese men undergoing radiotherapy for localized prostate cancer.
  International journal of radiation oncology, biology, physics 2004 Millender LE, Aubin M, Pouliot J, Shinohara K, Roach M
• Reducing the toxicity associated with the use of radiotherapy in men with localized prostate cancer.
  The Urologic clinics of North America 2004 Roach M
• Treatment margins and prostate brachytherapy: "size matters," but how much and where?
  Cancer journal (Sudbury, Mass.) 2004 Roach M
• Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV.
  International journal of radiation oncology, biology, physics 2004 Michalski JM, Winter K, Purdy JA, Perez CA, Ryu JK, Parliament MB, Valicenti RK, Roach M, Sandler HM, Markoe AM, Cox JD
• Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004 Scher HI, Eisenberger M, D'Amico AV, Halabi S, Small EJ, Morris M, Kattan MW, Roach M, Kantoff P, Pienta KJ, Carducci MA, Agus D, Slovin SF, Heller G, Kelly WK, Lange PH, Petrylak D, Berg W, Higano C,…
• Neoadjuvant hormonal therapy in men being treated with radiotherapy for localized prostate cancer.
  Reviews in urology 2004 Roach M
• Hormonal therapy and radiotherapy for localized prostate cancer: who, where and how long?
  The Journal of urology 2003 Roach M
• Third international conference on innovations and challenges in prostate cancer: prevention, detection and treatment.
  The Journal of urology 2003 Carroll PR, Benaron DA, Blackledge G, Coakley FV, D'Amico AV, Higano CS, Iversen P, Kattan M, Nanus DM, Nelson JB, Oh WK, Roach M, Sellers WR, Smith MR, McMann MC, Kantoff PW
• Commentary on a multi-institutional analysis of external beam radiotherapy for T1-T2 prostate cancer: "love the one you're with" and "do the right thing".
  International journal of radiation oncology, biology, physics 2003 Roach M
• A zero PSA slope in posttreatment prostate-specific antigen supports cure of patients with long-term follow-up after external beam radiotherapy for localized prostate cancer.
  International journal of radiation oncology, biology, physics 2003 Takamiya R, Weinberg V, Young CD, Sandler H, McLaughlin P, Roach M
• (Non)-migration of radiopaque markers used for on-line localization of the prostate with an electronic portal imaging device.
  International journal of radiation oncology, biology, physics 2003 Pouliot J, Aubin M, Langen KM, Liu YM, Pickett B, Shinohara K, Roach M
• Preliminary evaluation of low-grade toxicity with conformal radiation therapy for prostate cancer on RTOG 9406 dose levels I and II.
  International journal of radiation oncology, biology, physics 2003 Michalski JM, Winter K, Purdy JA, Wilder RB, Perez CA, Roach M, Parliament MB, Pollack A, Markoe AM, Harms W, Sandler HM, Cox JD
• "Supplemental beam" and prostate brachytherapy: a simple answer to a complicated question?
  International journal of radiation oncology, biology, physics 2003 Roach M
• Serum prostate-specific antigen and survival after external beam radiotherapy for carcinoma of the prostate.
  Urology 2003 Roach M, Weinberg V, McLaughlin PW, Grossfeld G, Sandler HM
• The evolving role of pelvic radiation therapy.
  Seminars in radiation oncology 2003 Roberts T, Roach M
• Race and survival of men treated for prostate cancer on radiation therapy oncology group phase III randomized trials.
  The Journal of urology 2003 Roach M, Lu J, Pilepich MV, Asbell SO, Mohiuddin M, Grignon D
• Radiation medicine innovations for the new millenium.
  Journal of the National Medical Association 2003 Heron DE, Godette KD, Wynn RA, Arterbery VE, Streeter OA, Roach M, Simpson JR, Blough M, Thomas CR
• Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy: a secondary analysis of the randomized protocol RTOG 86-10.
  International journal of radiation oncology, biology, physics 2002 Shipley WU, Lu JD, Pilepich MV, Heydon K, Roach M, Wolkov HB, Sause WT, Rubin P, Lawton CA, Machtay M
• Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma.
  The Journal of thoracic and cardiovascular surgery 2002 Lee TT, Everett DL, Shu HK, Jahan TM, Roach M, Speight JL, Cameron RB, Phillips TL, Chan A, Jablons DM
• Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy).
  International journal of radiation oncology, biology, physics 2002 Ryu JK, Winter K, Michalski JM, Purdy JA, Markoe AM, Earle JD, Perez CA, Roach M, Sandler HM, Pollack A, Cox JD
• Interobserver variability leads to significant differences in quantifiers of prostate implant adequacy.
  International journal of radiation oncology, biology, physics 2002 Lee WR, Roach M, Michalski J, Moran B, Beyer D
• Radical prostatectomy or external beam radiotherapy: one step forward or two steps back?
  Cancer 2002 Roach M
• Prostate-specific antigen in prostate cancer: a case study in the development of a tumor marker to monitor recurrence and assess response.
  Seminars in oncology 2002 Small EJ, Roach M
• The effect of beam energy and number of fields on photon-based IMRT for deep-seated targets.
  International journal of radiation oncology, biology, physics 2002 Pirzkall A, Carol MP, Pickett B, Xia P, Roach M, Verhey LJ
• Trade-off to low-grade toxicity with conformal radiation therapy for prostate cancer on Radiation Therapy Oncology Group 9406.
  Seminars in radiation oncology 2002 Michalski JM, Winter K, Purdy JA, Wilder R, Perez CA, Roach M, Parliament M, Pollack A, Markoe A, Harms WB, Sandler H, Cox JD
• Changing face and different countenances of prostate cancer: racial and geographic differences in prostate-specific antigen (PSA), stage, and grade trends in the PSA era.
  International journal of cancer 2001 Jani AB, Vaida F, Hanks G, Asbell S, Sartor O, Moul JW, Roach M, Brachman D, Kalokhe U, Muller-Runkel R, Ray P, Ignacio L, Awan A, Weichselbaum RR, Vijayakumar S
• Clinical staging of prostate cancer: reproducibility and clarification of issues.
  International journal of cancer 2001 Campbell T, Blasko J, Crawford ED, Forman J, Hanks G, Kuban D, Montie J, Moul J, Pollack A, Raghavan D, Ray P, Roach M, Steinberg G, Stone N, Thompson I, Vogelzang N, Vijayakumar S
• Radiation Therapy Oncology Group. Research Plan 2002-2006. Genitourinary Cancer Committee.
  International journal of radiation oncology, biology, physics 2001 Sandler H, Shipley WU, Gomella L, Pienta K, Bard RH, Bruner D, Clark R, DeSilvio M, Gaspar L, Gillin M, Grignon D, Hammond E, Hanks G, Heydon KH, Kaufman DS, Lee WR, Michalski J, Mydlo J, Pisansky T, …
• Radiation Therapy Oncology Group. Research Plan 2002-2006. Outcomes Committee.
  International journal of radiation oncology, biology, physics 2001 Watkins Bruner D, Berk L, Bondy M, Kachnic LA, Konski A, Layne E, Lee WR, Choucair A, Movsas B, Okunieff P, Roach M, Scott C, Vijayakumar S, Wenzel L, Radiation Therapy Oncology Group
• NCCN Practice Guidelines for Prostate Cancer.
  Oncology (Williston Park, N.Y.) 2000 Bahnson RR, Hanks GE, Huben RP, Kantoff P, Kozlowski JM, Kuettel M, Lange PH, Logothetis C, Pow-Sang JM, Roach M, Sandler H, Scardino PT, Taylor RJ, Urban DA, Walsh PC, Wilson TG, National …
• Three-dimensional conformal external beam radiotherapy or brachytherapy: which is the "best alternative" to radical prostatectomy?
  CA: a cancer journal for clinicians 2000 Roach M
• Fifteen-year minimum follow-up of a prostate brachytherapy series: comparing the past with the present.
  Urology 2000 Roach M, Hsu I
• Potency preservation after three-dimensional conformal radiotherapy for prostate cancer: preliminary results.
  American journal of clinical oncology 2000 Wilder RB, Chou RH, Ryu JK, Stern RL, Wong MS, Ji M, Roach M, White RD
• Definitive external beam irradiation in stage T1 and T2 carcinoma of the prostate. American College of Radiology. ACR Appropriateness Criteria.
  Radiology 2000 Perez CA, Beyer DC, Blasko JC, Forman JD, Hussey DH, Lee WR, Paryani SB, Pollack A, Potters L, Roach M, Scardino P, Schellhammer P, Leibel S
• Locally advanced (high-risk) prostate cancer. American College of Radiology. ACR Appropriateness Criteria.
  Radiology 2000 Pollack A, Paryani SB, Hussey D, Perez CA, Beyer DC, Blasko JC, Forman JD, Lee WR, Potters L, Roach M, Scardino P, Schellhammer P, Leibel S
• Node-positive prostate cancer. American College of Radiology. ACR Appropriateness Criteria.
  Radiology 2000 Lee WR, Pollack A, Perez CA, Beyer DC, Blasko JC, Forman JD, Hussey DH, Paryani SB, Potters L, Roach M, Scardino P, Schellhammer P, Leibel S
• Permanent source brachytherapy for prostate cancer. American College of Radiology. ACR Appropriateness Criteria.
  Radiology 2000 Potters L, Perez CA, Beyer DC, Blasko JC, Forman JD, Hussey DH, Lee WR, Paryani SB, Pollack A, Roach M, Scardino P, Schellhammer P, Leibel S
• Postradical prostatectomy irradiation in carcinoma of the prostate. American College of Radiology. ACR Appropriateness Criteria.
  Radiology 2000 Perez CA, Beyer DC, Blasko JC, Forman JD, Hussey DH, Lee WR, Paryani SB, Pollack A, Potters L, Roach M, Scardino P, Schellhammer P, Leibel S
• Staging evaluation for patients with adenocarcinoma of the prostate. American College of Radiology. ACR Appropriateness Criteria.
  Radiology 2000 Forman JD, Lee WR, Roach M, Perez CA, Beyer DC, Blasko JC, Hussey DH, Paryani SB, Pollack A, Potters L, Scardino P, Schellhammer P, Leibel S
• Minimal toxicity with 3-FAT radiotherapy of prostate cancer.
  Seminars in urologic oncology 2000 Weil MD, Crawford ED, Cornish P, Dzingle W, Stuhr K, Pickett B, Roach M
• Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406.
  International journal of radiation oncology, biology, physics 2000 Michalski JM, Purdy JA, Winter K, Roach M, Vijayakumar S, Sandler HM, Markoe AM, Ritter MA, Russell KJ, Sailer S, Harms WB, Perez CA, Wilder RB, Hanks GE, Cox JD
• Is the use of anti-androgen monotherapy appropriate in patients with advanced prostate cancer?
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000 Roach M, Reese D, Weinberg V, Small EJ, Carroll PR
• Does race influence survival for esophageal cancer patients treated on the radiation and chemotherapy arm of RTOG #85-01?
  International journal of radiation oncology, biology, physics 1999 Streeter OE, Martz KL, Gaspar LE, Delrowe JD, Asbell SO, Salter MM, Roach M
• Re: Race, prostate cancer survival, and membership in a large health maintenance organization.
  Journal of the National Cancer Institute 1999 Roach M, Forte D, Alexander M
• Interfraction interval does not affect survival of patients with non-small cell lung cancer treated with chemotherapy and/or hyperfractionated radiotherapy: a multivariate analysis of 1076 RTOG patients.
  International journal of radiation oncology, biology, physics 1999 Werner-Wasik M, Scott C, Graham ML, Smith C, Byhardt RW, Roach M, Andras EJ
• Management of locally advanced prostate cancer: new definitions and strategies.
  The Western journal of medicine 1998 Roach M
• Centralized multiinstitutional postimplant analysis for interstitial prostate brachytherapy.
  International journal of radiation oncology, biology, physics 1998 Bice WS, Prestidge BR, Grimm PD, Friedland JL, Feygelman V, Roach M, Prete JJ, Dubois DF, Blasko JC
• Sociodemographic analysis of patients in radiation therapy oncology group clinical trials.
  International journal of radiation oncology, biology, physics 1998 Chamberlain RM, Winter KA, Vijayakumar S, Porter AT, Roach M, Streeter O, Cox JD, Bondy ML
• Localization of the prostatic apex for radiotherapy treatment planning using urethroscopy.
  International journal of radiation oncology, biology, physics 1997 Wilder RB, Fone PD, Rademacher DE, Jones CD, Roach M, Earle JD, White RD
• Comparison of treatment techniques for conformal radiotherapy of the prostate using dose-volume histograms and normal tissue complication probabilities.
  Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1996 Roach M
• Markers, CTs, urethrograms, and the prostatic apex.
  International journal of radiation oncology, biology, physics 1995 Roach M, Holland J, Chan A, Shrieve D
• Calcium mass in human aortas from autopsy.
  Physiological measurement 1994 Sherebrin MH, Kim HL, Roach MR
• Participation in clinical trials: is it state-of-the-art treatment for African Americans and other people of color?
  Journal of the National Medical Association 1994 Thomas CR, Pinto HA, Roach M, Vaughn CB
• Bilateral arcs using "averaged beam's eye views": a simplified technique for delivering 3-D based conformal radiotherapy.
  Medical dosimetry : official journal of the American Association of Medical Dosimetrists 1994 Roach M, Akazawa PF, Pickett B, Purser P, Parkinson D, Meyler TS, Margolis LW
• Analysis of early and late deaths on RTOG non-small cell carcinoma of the lung trials: comparison with CALGB 8433.
  Lung cancer (Amsterdam, Netherlands) 1993 Komaki R, Pajak TF, Byhardt RW, Emami B, Asbell SO, Roach M, Pedersen JE, Curran WJ, Lattin P, Russell AH
• Re: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer.
  The Journal of urology 1993 Roach M
• Interruptions of high-dose radiation therapy decrease long-term survival of favorable patients with unresectable non-small cell carcinoma of the lung: analysis of 1244 cases from 3 Radiation Therapy Oncology Group (RTOG) trials.
  International journal of radiation oncology, biology, physics 1993 Cox JD, Pajak TF, Asbell S, Russell AH, Pederson J, Byhardt RW, Emami B, Roach M
• Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: preliminary results of a randomized, open-labeled, phase II trial.
  International journal of radiation oncology, biology, physics 1993 Vijayakumar S, Roach M, Wara W, Chan SK, Ewing C, Rubin S, Sutton H, Halpern H, Awan A, Houghton A
• Factors in the initiation and propagation of aortic dissections in human autopsy aortas.
  Journal of biomechanical engineering 1993 Tiessen IM, Roach MR
• Comparison of prognostic factors and survival among black patients and white patients treated with irradiation for non-small-cell lung cancer.
  Journal of the National Cancer Institute 1992 Graham MV, Geitz LM, Byhardt R, Asbell S, Roach M, Urtasun RC, Curran WJ, Lattin P, Russell AH, Cox JD
• The prognostic significance of race and survival from laryngeal carcinoma.
  Journal of the National Medical Association 1992 Roach M, Alexander M, Coleman JL
• A digital-radiographic technique for in vitro tissue thickness measurement using iodine displacement.
  Medical physics 1992 Holdsworth DW, Dunmore PJ, Roach MR, Fenster A
• Race and survival from intracranial ependymomas in children.
  International journal of radiation oncology, biology, physics 1991 Roach M, Alexander M, Coleman JL
• Rapidly alternating radiotherapy and high dose cisplatin chemotherapy in stage IIIB non-small cell lung cancer: results of a phase I/II study.
  International journal of radiation oncology, biology, physics 1991 Gandara DR, Valone FH, Perez EA, Deisseroth AB, Roach M, Ahn DK, Phillips T
• Prognostic factors for patients relapsing after radiotherapy for early-stage Hodgkin's disease.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990 Roach M, Brophy N, Cox R, Varghese A, Hoppe RT